Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines

Blood

Volumn 114, Issue 9, 2009, Pages 1842-1851

  Jedidi, Abire ^a,b,c   Marty, Caroline ^a,b,c   Oligo, Charleen ^a,b,c   Jeanson Leh, Laurence ^a,c,d   Ribeil, Jean Antoine ^e   Casadevall, Nicole ^a,f   Galy, Anne ^a,c,d   Vainchenker, William ^a,b,c   Villeval, Jean Luc ^a,b,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b IGR   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d GÉNÉTHON   (France)

^e CNRS   (France)

^f HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZ 960; ENZYME INHIBITOR; ERYTHROPOIETIN; JANUS KINASE 2; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT5 PROTEIN; UNCLASSIFIED DRUG; CD34 ANTIGEN; CYTOKINE; JAK2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REDUCTION; BIOSYNTHESIS; CELL LINE; CELL STRAIN K 562; GENE EXPRESSION REGULATION; METABOLISM; MUTATION; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIGENS, CD34; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASE 2; K562 CELLS; MUTATION; PHOSPHORYLATION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 70349232895     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-176875     Document Type: Article

References (37)

1. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol. 2004;41:1-5. (Pubitemid 38657103)
2. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2003:200-224.
3. Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera [letter]. N Engl J Med. 1974;290:1382.
4. Taksin AL, Couedic JP, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood. 1999;93:125-139. (Pubitemid 29019396)
5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148. (Pubitemid 40663494)
6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061. (Pubitemid 40386783)
7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397. (Pubitemid 40544655)
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790. (Pubitemid 40570926)
9. Villeval JL, James C, Pisani DF, Casadevall N, Vainchenker W. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. Semin Thromb Hemost. 2006;32:341-351.
10. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270. (Pubitemid 44125998)
11. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468. (Pubitemid 46193073)
12. Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest. 2007;117:2067-2074.
13. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22:23-30.
14. Martinez LA, Naguibneva I, Lehrmann H, et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A. 2002;99:14849-14854. (Pubitemid 35334572)
15. Miller VM, Xia H, Marrs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A. 2003;100:7195-7200. (Pubitemid 36706415)
16. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003;63:5198-5202. (Pubitemid 37139827)
17. Gozgit JM, Bebernitz G, Patil P, et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/Bcl-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008;283:32334-32343.
18. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550-553. (Pubitemid 34408678)
19. Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P. Lentiviral-mediated RNA interference. Hum Gene Ther. 2002;13:2197-2201.
20. Olivier A, Jeanson-Leh L, Bouma G, et al. A partial down-regulation of WASP is sufficient to inhibit podosome formation in dendritic cells. Mol Ther. 2006;13:729-737.
21. Cabane C, EnglaroW, Yeow K, Ragno M, Derijard B. Regulation of C2C12 myogenic terminal differentiation by MKK3/p38α pathway. Am J Physiol. 2003;284:C658-C666. (Pubitemid 36237518)
22. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia. 2006;20:350-353. (Pubitemid 43148676)
23. Levine RL, Belisle C,Wadleigh M, et al. X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis. Blood. 2006;107:4139-4141.
24. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia. 2006;20:471-476. (Pubitemid 43291746)
25. Jones AV, Bunyan DJ, Cross NC. No evidence for amplification of V617F JAK2 in myeloproliferative disorders. Leukemia. 2007;21:2561-2563. (Pubitemid 350148909)
26. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652-1660. (Pubitemid 44316134)
27. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111:3931-3940.
28. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006;108:2435-2437.
29. DuPont S, Masse A, James C, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110:1013-1021. (Pubitemid 47267441)
30. Verstovsek S, Kantarjian HM, Pardanani AD, et al. Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F:WT JAK2 ratio in patients with high allele burdens despite profound clinical improvement following treatment with the JAK inhibitor, INCB018424 [abstract]. Blood. 2008;112:Abstract 2802.
31. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385-395. (Pubitemid 28232083)
32. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566. (Pubitemid 26151518)
33. Appel S, Balabanov S, Brummendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells. 2005;23:1082-1088. (Pubitemid 41377724)
34. Miller VM, Gouvion CM, Davidson BL, Paulson HL. Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res. 2004;32:661-668.
35. Verstovsek S, Kantarjian HM, Pardanani AD, et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/ essential thrombocythemia myelofibrosis (post PV/ETMF) [abstract]. Blood. 2008;112:Abstract 1762.
36. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13:311-320.
37. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-325.